also reported that the delivery of STING agonist plus a Toll-like receptor 4 (TLR4) agonist through immunostimulatory nanoparticle (immuno-NP) could increase the local infiltration of IFNβ in pancreatic tumors. The gene discussed is STING1; the disease is pancreatic neoplasm.